Opinion | Published:

NK3 receptor antagonists: the next generation of antipsychotics?

Nature Reviews Drug Discovery volume 4, pages 967975 (2005) | Download Citation

Subjects

Abstract

Although current antipsychotic drugs are effective at treating the psychotic (positive) symptoms of schizophrenia, they have one or more serious side effects, including extrapyramidal symptoms, weight gain, cardiovascular liabilities and type II diabetes. However, recent data from clinical trials of selective neurokinin 3 (NK3) receptor antagonists in schizophrenia ? osanetant and talnetant ? have shown significant improvement in positive symptoms, with no major side-effects reported as yet. Here we discuss the preclinical and clinical evidence that indicates that NK3 receptor antagonists might represent a new approach to the treatment of schizophrenia and possibly other neuropsychiatric disorders.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    & Phenotype of schizophrenia: a review and formulation. Mol. Psychiatry 10, 27?39 (2004).

  2. 2.

    et al. Memory impairments identified in people at ultra-high risk for psychosis who later develop first-episode psychosis. Am. J. Psychiatry 162, 71?78 (2005).

  3. 3.

    et al. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl.) 124, 57?73 (1996).

  4. 4.

    & The dopamine hypothesis of schizophrenia: a review. Schizophr. Bull. 2, 19?76 (1976).

  5. 5.

    , , & New generation antipsychotics versus low-potency conventional anti-psychotics: a systematic review and meta-analysis. Lancet 361, 1581?1589 (2003).

  6. 6.

    , & Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J. Pharmacol. Exp. Ther. 251, 238?246 (1989).

  7. 7.

    et al. 5-Hydroxytryptamine2A receptor inverse agonists as antipsychotics. J. Pharmacol. Exp. Ther. 299, 268?276 (2001).

  8. 8.

    , , & Serotonin receptors: their role in drugs to treat schizophrenia. Progr. Neuropsychopharmacol. Biol. Psychiatry 27, 1159?1172 (2003).

  9. 9.

    Neurokinin antagonists and their potential role in treating depression and other stress disorders. Expert Opin. Ther. Patents 14, 1421?1433 (2004).

  10. 10.

    et al. SR142801, the first potent non-peptide antagonist of the tachykinin NK3 receptor. Life Sci. 56, PL27?PL32 (1995).

  11. 11.

    et al. Nonpeptide tachykinin receptor antagonists: I. Pharmacological and pharmacokinetic characterization of SB223412, a novel, potent and selective neurokinin-3 receptor antagonist. J. Pharmacol. Exp. Ther. 281, 1303?1311 (1997).

  12. 12.

    et al. Tachykinins and tachykinin receptors: structure and activity relationships. Curr. Med. Chem. 11, 2045?2081 (2004).

  13. 13.

    , & Tissue specific generation of two preprotachykinin mRNAs from one gene by alternative splicing. Nature 312, 729?734 (1984).

  14. 14.

    Substance P precursor and kininogen: their structures, gene organizations and regulation. Physiol. Rev. 67, 1117?1142 (1987).

  15. 15.

    , , & Structure and gene organization of bovine neuromedin K precursor. Proc. Natl Acad. Sci. USA 83, 7074?7078 (1986).

  16. 16.

    Mammalian tachykinin receptors. Annu. Rev. Neurosci. 14, 123?136 (1991).

  17. 17.

    The troubled story of tachykinins and neurokinins. Trends Pharmacol. Sci. 21, 173?175 (2000).

  18. 18.

    , & Tachykinin receptors: a radioligand binding perspective. J. Neurochem. 60, 1987?2009 (1993).

  19. 19.

    , & Pharmacology of tachykinin receptors on neurons in the ventral tegmental area of rat brain slices. Eur. J. Pharm. 273, 113?119 (1995).

  20. 20.

    et al. Highly selective agonists for substance P receptor subtypes. EMBO J. 5, 2805?2808 (1986).

  21. 21.

    , , & Identification of methionine134 and alanine146 in the second transmembrane segment of the human tachykinin NK receptor as residues involved in species selective binding to SR48968. Biochem. Biophys. Res. Commun. 198, 961?966 (1994).

  22. 22.

    , & In situ hybridization analysis of the distribution of neurokinin-3 mRNA in the rat central nervous system. J. Comp. Neurol. 372, 395?414 (1996).

  23. 23.

    , , , & Detailed distribution of neurokinin 3 receptors in the rat, guinea pig and gerbil brain: a comparative autoradio- graphic study. Neuropharmacology 40, 242?253 (2001).

  24. 24.

    Localization of striatal and nigral tachykinin receptors in the rat. Brain Res. 646, 13?18 (1994).

  25. 25.

    The neuropathology of schizophrenia. A critical review of the data and their interpretation. Brain 122, 593?624 (1999).

  26. 26.

    , & Increased spontaneous activity following substance P infusion into A10 dopaminergic area. Nature 276, 616?618 (1978).

  27. 27.

    , & Increased dopamine metabolism in rat striatum after infusion of substance P into the substantia nigra. Brain Res. 159, 223?227 (1978).

  28. 28.

    , & Injection of tachykinins and selective neurokinin receptor ligands into the substantia nigra reticulate increases striatal dopamine and 5-hydroxytryptamine metabolism. Eur. J. Pharm. 195, 107?114 (1991).

  29. 29.

    , & The selective NK3 receptor agonist senktide excites a subpopulation of dopamine-sensitive neurons in the rat substantia nigra pars compacta in vitro . Br. J. Pharmacol. 105, 3?5 (1992).

  30. 30.

    , , , & Tachykinin neurokinin-1 and neurokinin-3 receptor-mediated responses in guinea-pig substantia nigra: an in vitro electrophysiological study. Neuroscience 78, 745?757 (1997).

  31. 31.

    et al. Evidence for modulation of dopamine-neuronal function by tachykinin NK3 receptor stimulation in gerbil mesencephalon cell cultures. Eur. J. Neurosci. 8, 801?808 (1996).

  32. 32.

    et al. Activation of dopaminergic and cholinergic neurotransmission by tachykinin NK3 receptor stimulation: an in vivo microdialysis approach in guinea pig. Neuropeptides 32, 481?488 (1998).

  33. 33.

    , , & Behavioural effects of selective tachykinin agonists in midbrain dopamine regions. Brain Res. 565, 254?262 (1991).

  34. 34.

    et al. Senktide, a selective neurokinin B-like agonist, elicits serotonin-mediated behaviour following intracisternal administration in the mouse. Neurosci. Lett. 80, 321?326 (1987).

  35. 35.

    , & The NK-3 tachykinin receptor agonist senktide elicits 5-HT-mediated behaviour following central or peripheral administration in mice and rats. Br. J. Pharm. 94, 285?287 (1988).

  36. 36.

    , & Neurokinins activate local glutamatergic inputs to serotonergic neurons of the dorsal raphe nucleus. Neuropsychopharmacology 27, 329?340 (2002).

  37. 37.

    & The organization of recent and remote memories. Nature Rev. Neurosci. 6, 119?130 (2005).

  38. 38.

    et al. The effect of tandospirone, a serotonin1A agonist, on memory function in schizophrenia. Biol. Psychiatry 49, 861?868 (2001).

  39. 39.

    et al. Permissive role of neurokinin NK3 receptors in NK1 receptor-mediated activation of the locus coeruleus revealed by SR142801. Synapse 43, 62?69 (2002).

  40. 40.

    , , & A placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder. Am. J. Psychiatry 161, 1?6 (2004).

  41. 41.

    , & The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 13, 261?276 (1987).

  42. 42.

    & The brief psychiatric rating scale. Psychol. Reports 10, 799?812 (1962).

  43. 43.

    ECDEU Assessment Manual for Psychopharmacology: Publication ADM 76?338 (ed. Guy, W.) 219?222 (US Department of Health, Education, and Welfare, Washington DC, 1976).

  44. 44.

    & The effect of clozapine, risperidone and olanzapine on cognitive function in schizophrenia. Schizophr. Bull. 25, 233?255 (1999).

  45. 45.

    et al. Variables associated with disparities in treatment of patients with schizophrenia and comorbid mood and anxiety disorders. Psychiatr. Serv. 52, 1216?1222 (2001).

  46. 46.

    & The prevalence of comorbid anxiety in schizophrenia, schizoaffective and bipolar disorder. Aust. N. Z. J. Psychiatry 32, 6?72 (1998).

  47. 47.

    , , & Adjunctive alprazolam for schizophrenia with panic anxiety: clinical observation and pathogenetic implications. Am. J. Psychiatry 145, 742?744 (1998).

  48. 48.

    et al. Randomized, double-blind study of SR142801 (Osanetant). A novel neurokinin-3 (NK3) receptor antagonist in panic disorder with pre- and posttreatment cholecystokinin tetrapeptide (CCK-4) challenges. Pharmacopsychiatry 38, 24?29 (2005).

Download references

Acknowledgements

The authors gratefully thank T. Ballard-Yardy, P. David-Pierson, M.-C. Hernandez, T. Hoffmann, F. Knoflach, S. Nick, S. Poli, R. Porter, M. Schmitt, P. Schnider, L. Steward, A. Sleight, H. Stadler and J. Wettstein for discussions, ideas, commitments and support. We thank P. Shugrue for providing Fig 2Bb and X. Langlois for providing Fig 2Bc.

Author information

Affiliations

  1. Will Spooren and Claus Riemer are at F. Hoffmann-La Roche, Pharmaceuticals Division, Psychiatry-Disease Area, Building 72-148, 4070 Basel, Switzerland.

    • Will Spooren
    •  & Claus Riemer
  2. Herbert Meltzer is at Psychiatric Hospital Vanderbilt, Suite 306 1601 23rd Avenue South, Nashville, Tennessee 37212, USA.

    • Herbert Meltzer

Authors

  1. Search for Will Spooren in:

  2. Search for Claus Riemer in:

  3. Search for Herbert Meltzer in:

Competing interests

W.S. and C.R. are employees of F. Hoffmann-La Roche, which is developing drugs that target neurokinin receptors. H.M. is a consultant to Acadia, AstraZeneca, Eli Lilly, GlaxoSmithKline, Janssen, Merck, Pfizer, Solvay and Wyeth.

Corresponding author

Correspondence to Will Spooren.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nrd1905

Further reading